Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 1, 2007, Pages 57-68

  Lewis, Bruce E ^a   Hursting, Marcie J ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Clinical Science Consulting   (United States)

Author keywords

Anticoagulant; Argatroban; Bivalirudin; Direct thrombin inhibitor; Heparin; Heparin induced thrombocytopenia; Lepirudin; Percutaneous coronary intervention; Thrombus

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; AMPHOTERICIN B; ARGATROBAN; CHLORPROMAZINE; DANAPAROID; DIAZEPAM; DIGOXIN; DOBUTAMINE; EPTIFIBATIDE; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; LIDOCAINE; LOW MOLECULAR WEIGHT HEPARIN; PARACETAMOL; PROCHLORPERAZINE; RETEPLASE; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG CHOICE; DRUG COST; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 33846517585     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.1.57     Document Type: Review

References (81)

1. Rice L. Heparin-induced thrombocytopenia. Myths and misconceptions (that will cause trouble for you and your patient). Arch. Intern. Med. 164, 1961-1964 (2004).
2. Jang IK, Hursting MJ. When heparins promote thrombosis: A revie of heparin-induced thrombocytopenia. Circulation 111, 2671-2683 (2005).
3. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia. Biological basis for treatment. Chest 127, 9S-20S (2005).
4. Francis JL, Palmer GJ, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75, 17-22 (2003).
5. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann. Thorac. Surg 76, 638-648 (2003).
6. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl), 311S-337S (2004).
7. Warkentin TE, Sheppard JAI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood online ahead of print (2006).
8. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/ heparin antibodies: An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107, 2307-2312 (2003).
9. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital. Heart J. 1, 39-42 (2000).
10. Bennett-Guerrero E, Slaughter TF, White WD et al. Preoperative anti-PF4/ heparin antibody level predicts adverse outcome after cardiac surgery. J. Thorac. Cardiovasc. Surg. 130, 1567-1572 (2005).
11. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344, 1286-1292 (2001).
12. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch. Intern. Med. 164, 361-369 (2004).
13. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med. 32, 976-980 (2004).
14. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129, 1407-1416 (2006).
15. Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J. Intern. Med. 252, 149-154 (2002).
16. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am. J. Hematol, 76, 240-244 (2004).
17. Das P, Ziada K, Steinhbubl SR, et al Heparin-induced thrombocytopenia and cardiovascular diseases. Am. Heart J. 152, 19-26 (2006).
18. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838-1843 (2001).
19. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Int. Med. 163, 1849-1856 (2003).
20. Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 99, 73-80 (1999).
21. Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100, 587-593 (1999).
22. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J. Thromb. Haemost. 3, 2428-2436 (2005).
23. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet. Cardiovasc. Interv. 57, 177-184 (2002).
24. Mahaffey KW, Lewis BE, Wildermann NM et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: Main results. J. Invasive Cardiol. 15, 611-616 (2003).
25. Argatroban Prescribing Information. Research Triangle Park NC: GlaxoSmithKline; 2005.
26. Angiomax® Prescribing Information. Parsippany NJ: The Medicines Company; 2005.
27. Refludan® Prescribing Information. Wayne and Montville NJ: Berlex Laboratories Inc; 2004.
28. Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J. Thorac. Cardiovasc. Surg. 13, 699-700 (2006).
29. De Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann. Pharmacother. 37, 1237-1240 (2003).
30. Baghdasarian S, Singh I, Militello M, Bartholomew J, Begelman S. Argatroban dosage in critically ill patients with HIT [abstr]. Blood 104, 493a (2004).
31. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 129, 1167-1175 (2006).
32. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 26, 452-460 (2006).
33. Tardy B. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108, 1492-1496 (2006).
34. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT and clinical relevance. Blood 96, 2373-2378 (2000).
35. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb. Haemost. 95, 967-981 (2006).
36. Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 89, 1017-1018 (2004).
37. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101, 21-37 (2003).
38. Matthai WH, Lewis BE, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 116, 121-126 (2005).
39. DeEugenio DL, Ruggiero N, Thomson LJ, Menajovsky LF, Herman JH. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: Case report and review of the literature. Pharmacotheraphy 25, 615-619 (2005).
40. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 127, 1S-8S (2005).
41. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br. J. Haematol. 133, 259-269 (2006).
42. Foo SY, Everett BM, Yeh R et al. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J. 152, 290 e1-7 (2006).
43. Gluckman TJ, Segal JB, Fredde NL et al. Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am. J. Cardiol. 95, 744-7 (2005).
44. Cruz D, Karlsberg R, Takano Y, Vora D, Tobis J. Subacute stent thrombosis associated with heparin-coated stent and heparin-induced thrombocytopenia. Catheter Cardiovasc. Interv. 58, 80-83 (2003).
45. McNutly I, Katz E, Kim KY. Thrombocytopenia following heparin flush. Progress Cardiovasc. Nurs. 20, 143-147 (2005).
46. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports. Cathet. Cardiovasc. Interv. 52, 468-472 (2001).
47. Pinto DS, Sperling RT, Tu RM, Cohen DJ, Carrozza JP. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet. Cardiovasc. Interv. 58, 65-68 (2003).
48. Cochran K, DeMartini TJ, Lewis BE, et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J. Invasive Cardiol. 15, 617-621 (2003).
49. Smith S, Feldman TE, Hirshfeld JW et al ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 113, 156-175 (2006).
50. Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J. Thromb. Thrombolysis 18, 31-37 (2004).
51. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: A literature analysis. J. Pediatr. Hematol. Oncol. 28, 4-10 (2006).
52. Bird JA, Chairman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J. 142, 952-959 (2001).
53. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289, 853-63 (2003).
54. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin in patients with suspeqed heparin-induced thrombocytopenia. Pharmacotherapy 25, 1736-1745 (2005).
55. Frame JN. The heparin-induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives. Semin. Hematol, 42, S28-S35 (2005).
56. Arnold RJ, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: The effect of early versus delayed treatment. Cardiol Rev. 14, 7-13 (2006).
57. Dang CH, Durkalski VI, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy, 26, 461-468 (2006).
58. Koster A, Hansen R, Kupps H, Hetzer R, Crystal GJ, Metzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients. J. Cardiothorac. Past. Anesth. 14, 243-248 (2000).
59. Laber A, Martin E, Kloecker H. Proposed guidelines fbr anticoagulation during cardiac surgery using argatroban [abstract]. Haematol, 91 (Suppl 1), 151-152 (2006).
60. Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy JH. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thmmbocytopenia. Ann Thorac. Surg. 80, 299-303 (2005).
61. Dyke CM, Smedira NG, Koster A et al A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study.J. Thorac. Cardiovarc. Surg. 131, 533-539 (2006).
62. Smedira, NG, Dyke CM, Koster A et al Anticoagulation with bivabrudin for off-pump coronary artery bypass grafting: The results ofthe EVOLUTION-OFF study. J. Thorac. Cardiovasc. Surg. 131, 686-692 (2006).
63. Greinacher A. Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108, 2062-2065 (2003).
64. Eichler P Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin am polyspecific and recognize epitopes on bivalirudin. Blaod 103, 613-616 (2004).
65. LaMonte MP, Brown PM, Hunting MJ. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Expert Rev Cardiovasc. Ther. 3, 31-41 (2005).
66. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 22 (6 pt 2), 105S-111S (2002).
67. Honikso ME, Fink JM, Militello MA, Mauro VF Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am. J. Health Syst. Pharm 61, 2415-2418 (2004).
68. Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst. Pharm 61, 1774, 1776 (2004).
69. Gosselin RC, Dager WE, King JH et al Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol, 121, 593-599 (2004).
70. Hunting MJ, Lewis BE, Macfarlane DE. Thrisitioning from argatroban to warfarin therapy in patients with beparin-induced thrombocytopenia. Clin Appl, Thromb. Hemost. 11, 279-287 (2005).
71. Sheth SB, DiCicco RA, Hunting MJ, Montague T, Jorkasky DK Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemost. 85,435-440 (2001).
72. Harder S, Graff J, Klinkhardt U et al Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: Effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb. Haemost. 91, 1137-1145 (2004).
73. Arpino, PA, Demirjian Z, Van Cott EM. Use ofthe chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 25, 157-164 (2005).
74. Fischer KG. Hirudin in renal insufficiency. Seinin. Thromb. Hemost. 28, 467-482 (2002).
75. Murray PM, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban treatment regimens during in end-stage renal disease. Kidney Int 66, 2446-2453 (2004).
76. Alsoufi B, Boshkov LK, Kirby A et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: An emerging cause of morbidity and mortality. Semin Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu. 7, 155-171 (2004).
77. Stratmann G, diSilva AM, Tseng EE et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombacytopenia. Anesth, Analg. 98, 1635-1639 (2004).
78. Yee AJ, Kuter DJ. Successful recovery from an overdose of argatroban. Ann Pharmacother. 40, 446-449 (2006).
79. Hallman SE, Hebbar L, Robinson J, Uber WE. The use of argatroban for carotid endarterectomy in heparin-induced thrombocvtopenia. Anesth. Analg. 100, 946-948 (2005).
80. Finks SW. Bivalirudin use in carotid endarerectomy in a patient with heparin-induced thrombocytopenia. Ann. Pharmacother. 40, 340-3 (2006).
81. Itoh T, Nonogi H, Miyasaki S et al. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: A prospective randomized pilot study. Circ. J. 68, 615-622 (2004).